798 related articles for article (PubMed ID: 19726788)
1. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.
Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ
Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog pathway inhibition and the race against tumor evolution.
Atwood SX; Chang AL; Oro AE
J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148
[TBL] [Abstract][Full Text] [Related]
4. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
Metcalfe C; de Sauvage FJ
Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
6. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily.
Kean S
Science; 2009 Sep; 325(5945):1188. PubMed ID: 19729622
[No Abstract] [Full Text] [Related]
7. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations.
Galimberti F; Busch AM; Chinyengetere F; Ma T; Sekula D; Memoli VA; Dragnev KH; Liu F; Johnson KC; Guo Y; Freemantle SJ; Andrew AS; Greninger P; Robbins DJ; Settleman J; Benes C; Dmitrovsky E
Int J Oncol; 2012 Nov; 41(5):1751-61. PubMed ID: 22923130
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
9. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
[TBL] [Abstract][Full Text] [Related]
10. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
[TBL] [Abstract][Full Text] [Related]
11. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.
Pricl S; Cortelazzi B; Dal Col V; Marson D; Laurini E; Fermeglia M; Licitra L; Pilotti S; Bossi P; Perrone F
Mol Oncol; 2015 Feb; 9(2):389-97. PubMed ID: 25306392
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM
Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299
[TBL] [Abstract][Full Text] [Related]
13. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
14. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
15. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.
Chenna V; Hu C; Pramanik D; Aftab BT; Karikari C; Campbell NR; Hong SM; Zhao M; Rudek MA; Khan SR; Rudin CM; Maitra A
Mol Cancer Ther; 2012 Jan; 11(1):165-73. PubMed ID: 22027695
[TBL] [Abstract][Full Text] [Related]
16. LKB1 inhibits breast cancer partially through repressing the Hedgehog signaling pathway.
Zhuang Z; Wang K; Cheng X; Qu X; Jiang B; Li Z; Luo J; Shao Z; Duan T
PLoS One; 2013; 8(7):e67431. PubMed ID: 23861764
[TBL] [Abstract][Full Text] [Related]
17. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.
Ishii T; Shimizu Y; Nakashima K; Kondo S; Ogawa K; Sasaki S; Matsui H
Eur J Pharmacol; 2014 Jan; 723():305-13. PubMed ID: 24291104
[TBL] [Abstract][Full Text] [Related]
18. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
19. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Buonamici S; Williams J; Morrissey M; Wang A; Guo R; Vattay A; Hsiao K; Yuan J; Green J; Ospina B; Yu Q; Ostrom L; Fordjour P; Anderson DL; Monahan JE; Kelleher JF; Peukert S; Pan S; Wu X; Maira SM; García-Echeverría C; Briggs KJ; Watkins DN; Yao YM; Lengauer C; Warmuth M; Sellers WR; Dorsch M
Sci Transl Med; 2010 Sep; 2(51):51ra70. PubMed ID: 20881279
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog signaling in basal cell carcinoma.
Otsuka A; Levesque MP; Dummer R; Kabashima K
J Dermatol Sci; 2015 May; 78(2):95-100. PubMed ID: 25766766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]